Amylyx Pharmaceuticals, Inc. - Common Stock (AMLX)
3.7400
-0.0600 (-1.58%)
Amylyx Pharmaceuticals is a biotechnology company focused on the development of innovative therapeutics for neurodegenerative diseases
The company aims to address significant unmet medical needs, particularly in conditions such as amyotrophic lateral sclerosis (ALS) and Alzheimer’s disease, through its proprietary drug candidates that target underlying biological processes. By leveraging scientific expertise and advanced research techniques, Amylyx is committed to delivering effective treatment options that enhance the quality of life for patients affected by these challenging conditions.
![](https://cdn.benzinga.com/files/images/story/2024/11/18/oil-prices-5079975_0.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · November 18, 2024
![](https://cdn.benzinga.com/files/images/story/2024/11/18/movers-image.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · November 18, 2024
![](https://cdn.benzinga.com/files/images/story/2024/11/18/Robinhood-Markets-Inc-.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · November 18, 2024
![](https://g.foolcdn.com/editorial/images/794548/person-in-a-lab-gazing-into-a-microscope.jpg)
The company seems to have a winner on its hands with a drug that targets a rare genetic disorder.
Via The Motley Fool · October 18, 2024
![](https://cdn.benzinga.com/files/images/story/2024/09/17/3-azioni-a-basso-prezzo-da-tenere-docchi.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · September 17, 2024
![](https://cdn.benzinga.com/files/images/story/2024/07/12/xrdDAFsc26aiRI2-j5041054601835708275-t23.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · July 12, 2024
![](https://cdn.benzinga.com/files/images/story/2024/07/10/bz-pharma-briefs_0.jpeg?width=1200&height=800&fit=crop)
Amylyx Pharmaceuticals acquired avexitide from Eiger BioPharmaceuticals Inc. for $35.1 million. Avexitide, a GLP-1 receptor antagonist, ready for Phase 3 trial for post-bariatric hypoglycemia and congenital hyperinsulinism.
Via Benzinga · July 10, 2024
![](https://investorplace.com/wp-content/uploads/2022/05/earnings-season-1600.png)
AMLX stock results show that Amylyx Pharma missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.
Via InvestorPlace · May 9, 2024
![](https://cdn.benzinga.com/files/images/story/2024/AMLX.png?width=1200&height=800&fit=crop)
Amylyx's AMX0035 data in treating Wolfram syndrome, with interim data indicating positive effects on diabetes progression, visual decline, and overall disease burden. Safety profile consistent.
Via Benzinga · April 10, 2024
![](https://www.investors.com/wp-content/uploads/2017/03/stock-pharmaceutical-2-adobe.jpg)
The company could now pull Relyvrio off the market.
Via Investor's Business Daily · March 8, 2024
![](https://cdn.benzinga.com/files/images/story/2024/Falling-Chart-As-A-Symbol-Of-Crisis--Eco_0.jpeg?width=1200&height=800&fit=crop)
Seelos Therapeutics updates Phase 2/3 HEALEY ALS trial with SLS-005, showing potential efficacy in subgroup analysis. Explore the latest data on ALS treatment with SLS-005."
Via Benzinga · March 19, 2024
![](https://investorplace.com/wp-content/uploads/2022/03/pharmaceuticals_tnxp_1600-1024x576.png)
Discover top pharma stocks to sell in March before they plummet. Learn why ACAD, AMLX and WST are on the list for urgent sell-off decisions.
Via InvestorPlace · March 14, 2024
![](https://cdn.benzinga.com/files/images/story/2024/03/08/image_3.jpg?width=1200&height=800&fit=crop)
U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite dipping around 0.5% on Friday. The Dow traded up 0.27% to 38,894.21 while the NASDAQ fell 0.51% to 16,190.52. The S&P 500 also fell, dropping, 0.20% to 5,146.8.
Via Benzinga · March 8, 2024
![](https://cdn.benzinga.com/files/images/story/2024/Wall-street-sign-in-New-York_2.jpeg?width=1200&height=800&fit=crop)
The stock market is navigating a mixed closing session this week, with the S&P 500 and Nasdaq 100 struggling to stave off a weekly downturn.
Via Benzinga · March 8, 2024
![](https://cdn.benzinga.com/files/images/story/2024/03/08/marvell_technology_-_logo.jpg?width=1200&height=800&fit=crop)
Shares of Marvell Technology, Inc. (NASDAQMRVL) fell sharply during Friday’s session after the company reported fourth-quarter financial results and issued weak Q1 guidance.
Via Benzinga · March 8, 2024
![](https://cdn.benzinga.com/files/images/story/2024/03/08/crude_oil_-_logo.jpg?width=1200&height=800&fit=crop)
U.S. stocks traded mixed midway through trading, with the Dow Jones index gaining around 80 points on Friday. The Dow traded up 0.21% to 38,874.05 while the NASDAQ fell 0.42% to 16,204.26. The S&P 500 also fell, dropping, 0.13% to 5,150.72.
Via Benzinga · March 8, 2024
![](https://cdn.benzinga.com/files/images/story/2024/Brainwave.jpeg?width=1200&height=800&fit=crop)
Amylyx Pharmaceuticals' AMX0035 trial results for ALS. Amylyx plans regulatory discussions and potential market actions. AMX0035's ongoing studies in PSP and Wolfram syndrome.
Via Benzinga · March 8, 2024
![](https://cdn.benzinga.com/files/images/story/2024/03/08/image21.jpeg?width=1200&height=800&fit=crop)
U.S. stocks traded higher this morning, with the Nasdaq Composite gaining over 50 points on Friday. Following the market opening Friday, the Dow traded up 0.04% to 38,805.52 while the NASDAQ rose 0.41% to 16,339.39. The S&P 500 also rose, gaining, 0.23% to 5,169.38.
Via Benzinga · March 8, 2024